Hospira recall drives 2 other drug companies to pull injectables from market

Two drug companies that use or repackage Hospira products launched secondary recalls in response to the drugmaker's June 15 recall of several injectable drugs.

Hospira initiated the recall after a routine simulation of its manufacturing process discovered the potential for microbial growth, suggesting microorganisms may be in the products.

PharMedium Services on June 26 recalled nearly 20 lots of its potassium phosphate and succinylcholine chloride injections distributed to healthcare facilities across the country. PharMedium's injectables are compounded using some Hospira products.

Fagron Sterile Services recalled three lots of its succinylcholine chloride injection at the hospital and clinic level June 23. The company purchases Hospira products and repackages them under their own label.

Neither PharMedium nor Fagron Sterile Services have received reports of adverse events associated with the recalled injectable drugs.

More articles on supply chain:

Viewpoint: 4 insights into postapproval monitoring of medical devices
6 drugmakers in the headlines
Philips acquires noninvasive neurodiagnostics company for $36M

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars